EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Identification of PPFIA3 as a Potential Prognostic and Immune Biomarker Through Pan‐Cancer Analysis

Xianghong Wang, Rong Lin, Chuanchuan Sun, Niujian Wu, Hongyun Lu

Organ Medicine · 2025

DOI: 10.1002/orm2.70008 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background As a member of the liprin‐α family of proteins, the functional relevance of PPFIA3 in cancer remains unclear. We aim to evaluate the role of PPFIA3 in pan‐cancer. Methods A large amount of RNA‐seq data was obtained from the TCGA and GTEx databases, using databases such as TISIDB, TIMER, cBioPortal, GEPIA2, HPA, CancerSEA, CellMiner, UALCAN, STRING, Sangerbox, Kaplan–Meier Plotter, and TISMO to analyze the correlation of PPFIA3 expression with tumor prognosis, immune infiltration levels, immune checkpoints, tumor mutational burden (TMB), microsatellite instability (MSI), methylation levels, immune therapy, drug sensitivity, and so forth. Results PPFIA3 expression is commonly elevated in most cancers and is associated with poor prognosis. Furthermore, high PPFIA3 expression significantly correlates with immune regulatory genes, immune checkpoints, TMB, MSI, and methylation status. Additionally, PPFIA3 expression is associated with immune cell composition and infiltration levels. Interestingly, in patients receiving anti‐PD‐L1 therapy, high PPFIA3 expression is associated with improved survival and prognosis. Further analysis suggests that PPFIA3 can serve as a predictive factor for responsiveness to immune checkpoint blockade therapy in breast cancer. Moreover, our results indicate a strong correlation between PPFIA3 and drug sensitivity. Conclusions This pan‐cancer study provides a comprehensive understanding of the critical role of PPFIA3 in human cancer and suggests that PPFIA3 may be a potential prognostic biomarker and therapeutic target for cancer immunotherapy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →